1/2 Disitimab Vedotin & toripalimab beating platinum chemotherapy in 1st line UC in HER2 +ves. HRs for PFS/OS =0.36/0.56 respectively. RR and CR rate of 76% & 5% respectively. Tox related discontinuation in 12 vs 10% respectively. Working across all subsets #ESMO25 OncoAlert

ImVigor011 presented by Tom Powles #ESMO25 🔮 CtDNA (+) predictive for improved PFS+OS w adjuvant atezolizumab post-cystectomy 🕰️ CtDNA measured up to 21 mos post-cystectomy 🧪 ctDNA (-) had 2 yr 88% RFS and 97% OS 🥪 Potential implications for sandwich chemoimmunotx inc EVP

1/4 IMVIGOR011 shows ctDNA is a useful predictive and prognostic tool post cystectomy in muscle invasive bladder cancer #ESMO25 . ctDNA positive patients had DFS and OS benifits with atezolizumab. ctDNA negative patients are at a low risk of relapse/cancer death. OncoAlert

Enfortumab vedotin with pembrolizumab treatment outcomes in patients with histologic subtypes of advanced #UrothelialCarcinoma: analysis of the #UNITE study. Presentation by Tanya Jindal UC San Francisco. #ESMO25 written coverage by Rashid K. Sayyid UA Urology > bit.ly/42LSDCI ESMO - Eur. Oncology

The UromigosLive 2025 meeting presents #UromigosShorts videos on GU Oncology topics. The videos with the most views win a prize at #UromigosLive November 7-8th in Nashville, TN. Below, Dr. Amanda Nizam discusses: Enfortumab Vedotin Toxicity.

Our analysis from the retrospective UNITE study shows activity of EVP across histologic subtypes, including modest activity in patients with pure variants. These findings warrant validation in larger cohorts. #ESMO25 UroToday.com Bladder Cancer Advocacy Network Vadim Koshkin MD

EV+P is a pivotal regimen in la/mUC & 🔜 expanding to MIUC. Proactive AE monitoring, pt 📚, & multidisciplinary collaboration are critical to optimizing safety & efficacy. 🚨 SJS/TEN, DKA, ILD 📋 Baseline & ongoing monitoring for AEs 🔑 Early ID & proactive dose modifications ⬇️

🎶 Wondering how to tackle variant histologies in bladder cancer? Think of them as music genres—same stage, different openers (neoadj.) and headliners (1st line tx). 🎤 From micropapillary to plasmacytoid—each has a style & strategy. 🎧 Watch here ⬇️ Uromigos David H Aggen, MD PhD

EV/Pembro has another positive trial (EFS & OS) in MIBC. This time vs chemo/surgery rather than just surgery (KN905 (pCR 57%)). Will these results be better than NIAGARA (chemo/durva OS-0.75). In M1 disease EVP>chemo/IO, but let’s see in MIBC. pfizer.com/news/press-rel…

Excited to share our new paper evaluating utilization of ICIs as subsequent therapy in patients randomized to the control arm of registrational genitourinary cancer trials. Pedro C Barata, MD MSc FACP Albert Jang, MD Jeffrey Zhong authors.elsevier.com/a/1mQw25YR3CiR…

Summary of treatment stratification in N+ bladder cancer👇🏼 EV-304, KN866, ENERGIZE and VOLGA will define perioperative intensification for cN1 and cN2-N3 should be approached as systemic disease europeanurology.com/article/S0302-… European Urology Oncology OncoAlert Petros Grivas Jose Daniel Subiela

Bladder cancer agenda ASCO GU #GU26 ctDNA in MIBC highlights. Updates from IM011 (atezo vs placebo in +ves and surveillance in -ves) what can we learn from ct DNA monitoring/levels (MTM) (rather than just +ve or -ve)? NIAGARA (periopertive durvalumab) explores the values of

Is the era of cisplatin over? The latest #BackTableTumorBoard features @AlanTanMD, Dr. Amanda Nizam, and Dr. Brad McGregor discussing the rapidly shifting MIBC landscape. Listen now: na2.hubs.ly/H03j5v90 #BladderCancer #OncTwitter #Immunotherapy #ONC45 #GUOnc

Excited to share our publication in CGUC - Tx sequencing post ICI in urothelial CA - preferred interval of >6mo & many ❓remain Ali Khaki Priyanka Chablani, MD, MS Petros Grivas Matt Galsky Shilpa Gupta Elizabeth Plimack MD @peterodonnell Jonathan Rosenberg MD Vadim Koshkin MD clinical-genitourinary-cancer.com/article/S1558-…

The time of day for cancer immunotherapy is associated with major outcomes. Early is better. Results from a randomized trial of lung cancer, backs up the importance of our circadian rhythm and immune system nature.com/articles/s4159…

Excited to share our work, as we now move EV+P to the MIBC space #GU26 Appreciate the mentorship from Jason Brown Vadim Koshkin MD in collab with Tanya Jindal Dimitra R. Bakaloudi MD, MS, MPA Salvador Jaime-Casas, MD Amanda Nizam, MD Pedro C Barata, MD MSc FACP Yousef Zakharia Petros Grivas #UNITE clinical-genitourinary-cancer.com/article/S1558-…

ctDNA data for radiotherapy (TMT) in muscle invasive bladder cancer shows 19/59 pts (32%) were ctDNA+ve at baseline (⬇️ than in NIAGARA 57%). 11/19 had ctDNA clearance with TMT. Those that didn’t clear had ⬆️ risk of systemic rather than local relapse, underlining TMTs role in

In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial

🔷 At UC San Francisco, a multidisciplinary team of clinicians and researchers is redefining the approach to treating patients with #bladdercancer: buff.ly/WCShAwS 📺 GU Oncology Now provides in-depth coverage of the work being done for patients with #MIBC and #NMIBC, featuring

How do you talk to patients about ctDNA? Cleveland Clinic's Amanda Nizam, MD explains how she uses it as a surveillance tool in bladder cancer — and how patients are increasingly engaged in tracking their results. 🎥 Watch: bit.ly/47RloR4 #BladderCancer #ctDNA